ID

20898

Description

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection; ODM derived from: https://clinicaltrials.gov/show/NCT00362635

Link

https://clinicaltrials.gov/show/NCT00362635

Keywords

Versions (1)
  1. 3/26/17 3/26/17 -
Uploaded on

March 26, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatitis B NCT00362635

English

Eligibility Hepatitis B NCT00362635

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. patient is between 18 and 60, inclusive.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. patient is hbv dna positive with dna levels at screening >= 3 x 1,000,000 copies/ml.
Description

Hbv DNA Positive | Hepatitis B DNA Measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1256114
UMLS CUI [1,2]
C1514241
UMLS CUI [2]
C3641250
3. patient is documented to be hbsag positive for > 6 months and hbeag positive.
Description

Hepatitis B surface antigen positive | Hepatitis B e antigen positive

Data type

boolean

Alias
UMLS CUI [1]
C0149709
UMLS CUI [2]
C0392390
4. patient has ast and alt levels which are >= 1 times and <= 10 times the upper limit of normal (x uln).
Description

Aspartate aminotransferase measurement | Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
5. patient has bilirubin levels <= 1.5 x uln or bilirubin levels > 1.5 x uln with diagnosis of gilbert's disease and conjugated bilirubin within normal limits.
Description

Serum total bilirubin measurement | Gilbert Disease | Bilirubin conjugated normal

Data type

boolean

Alias
UMLS CUI [1]
C1278039
UMLS CUI [2]
C0017551
UMLS CUI [3]
C0855626
6. women of childbearing age must have a negative urine (b-hcg) pregnancy test before start of trial treatment.
Description

Childbearing Potential Urine pregnancy test Negative

Data type

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0430056
UMLS CUI [1,3]
C1513916
7. patient is able to give written informed consent prior to study start and to comply with the study requirements.
Description

Informed Consent | Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
Description

Antiviral Therapy | Biological Response Modifiers | Adrenal Cortex Hormones

Data type

boolean

Alias
UMLS CUI [1]
C0280274
UMLS CUI [2]
C0005525
UMLS CUI [3]
C0001617
2. patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for hbv infection.
Description

Lamivudine | lobucavir | adefovir | famciclovir | Nucleoside Investigational | Hepatitis B

Data type

boolean

Alias
UMLS CUI [1]
C0209738
UMLS CUI [2]
C0286536
UMLS CUI [3]
C0050175
UMLS CUI [4]
C0209227
UMLS CUI [5,1]
C0028621
UMLS CUI [5,2]
C1517586
UMLS CUI [6]
C0019163
3. previous treatment with interferon must have ended at least 6 months prior to the screening visit.
Description

Interferon To be stopped

Data type

boolean

Alias
UMLS CUI [1,1]
C0021747
UMLS CUI [1,2]
C1272691
4. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
Description

Ascites | Bleeding varices | Hepatic Encephalopathy

Data type

boolean

Alias
UMLS CUI [1]
C0003962
UMLS CUI [2]
C0333106
UMLS CUI [3]
C0019151
5. patient is co-infected with hcv or hiv.
Description

HCV coinfection | HIV coinfection

Data type

boolean

Alias
UMLS CUI [1]
C1698259
UMLS CUI [2]
C4062778
6. patient has evidence of decompensated cirrhosis or hepatocellular carcinoma (alpha fetoprotein).
Description

Decompensated cirrhosis Evidence of | Liver carcinoma | Alpha one fetoprotein measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1619727
UMLS CUI [1,2]
C0332120
UMLS CUI [2]
C2239176
UMLS CUI [3]
C0201539
7. patient is pregnant or breast-feeding.
Description

Pregnancy | Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
8. patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal, or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with spermicide or abstinence).
Description

Contraceptive methods Unwilling | Condoms, Male | Female Sterilization | Hysterectomy | Bilateral tubal ligation | Postmenopausal state | Contraception, Barrier | Intrauterine Devices | Vaginal Spermicides | Sexual Abstinence

Data type

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C0558080
UMLS CUI [2]
C0009653
UMLS CUI [3]
C0015787
UMLS CUI [4]
C0020699
UMLS CUI [5]
C0589114
UMLS CUI [6]
C0232970
UMLS CUI [7]
C0004764
UMLS CUI [8]
C0021900
UMLS CUI [9]
C0087145
UMLS CUI [10]
C0036899
9. patient has a clinically relevant history of abuse of alcohol or drugs.
Description

Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0038586
10. patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
Description

Gastrointestinal Diseases | Kidney Diseases | Decompensated liver disease | Bronchopulmonary disease | nervous system disorder | Cardiovascular Diseases | Malignant Neoplasms | Hypersensitivity

Data type

boolean

Alias
UMLS CUI [1]
C0017178
UMLS CUI [2]
C0022658
UMLS CUI [3]
C4075847
UMLS CUI [4]
C1096000
UMLS CUI [5]
C0027765
UMLS CUI [6]
C0007222
UMLS CUI [7]
C0006826
UMLS CUI [8]
C0020517
11. subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to screening visit.
Description

Study Subject Participation Status | Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
12. subjects who are taking any traditional chinese medication, or has been taking any traditional chinese medication within the last 2 weeks prior to screening visit.
Description

Pharmaceutical Preparation Traditional Chinese Medicine

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0025124
13. any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.
Description

Criteria Protocol Compliance Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C0525058
UMLS CUI [1,3]
C1299582
Back to the top of the page

Similar models

Eligibility Hepatitis B NCT00362635

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. patient is between 18 and 60, inclusive.
boolean
C0001779 (UMLS CUI [1])
Hbv DNA Positive | Hepatitis B DNA Measurement
Item
2. patient is hbv dna positive with dna levels at screening >= 3 x 1,000,000 copies/ml.
boolean
C1256114 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C3641250 (UMLS CUI [2])
Hepatitis B surface antigen positive | Hepatitis B e antigen positive
Item
3. patient is documented to be hbsag positive for > 6 months and hbeag positive.
boolean
C0149709 (UMLS CUI [1])
C0392390 (UMLS CUI [2])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement
Item
4. patient has ast and alt levels which are >= 1 times and <= 10 times the upper limit of normal (x uln).
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
Serum total bilirubin measurement | Gilbert Disease | Bilirubin conjugated normal
Item
5. patient has bilirubin levels <= 1.5 x uln or bilirubin levels > 1.5 x uln with diagnosis of gilbert's disease and conjugated bilirubin within normal limits.
boolean
C1278039 (UMLS CUI [1])
C0017551 (UMLS CUI [2])
C0855626 (UMLS CUI [3])
Childbearing Potential Urine pregnancy test Negative
Item
6. women of childbearing age must have a negative urine (b-hcg) pregnancy test before start of trial treatment.
boolean
C3831118 (UMLS CUI [1,1])
C0430056 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
Informed Consent | Protocol Compliance
Item
7. patient is able to give written informed consent prior to study start and to comply with the study requirements.
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Antiviral Therapy | Biological Response Modifiers | Adrenal Cortex Hormones
Item
1. patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy.
boolean
C0280274 (UMLS CUI [1])
C0005525 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
Lamivudine | lobucavir | adefovir | famciclovir | Nucleoside Investigational | Hepatitis B
Item
2. patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for hbv infection.
boolean
C0209738 (UMLS CUI [1])
C0286536 (UMLS CUI [2])
C0050175 (UMLS CUI [3])
C0209227 (UMLS CUI [4])
C0028621 (UMLS CUI [5,1])
C1517586 (UMLS CUI [5,2])
C0019163 (UMLS CUI [6])
Interferon To be stopped
Item
3. previous treatment with interferon must have ended at least 6 months prior to the screening visit.
boolean
C0021747 (UMLS CUI [1,1])
C1272691 (UMLS CUI [1,2])
Ascites | Bleeding varices | Hepatic Encephalopathy
Item
4. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
boolean
C0003962 (UMLS CUI [1])
C0333106 (UMLS CUI [2])
C0019151 (UMLS CUI [3])
HCV coinfection | HIV coinfection
Item
5. patient is co-infected with hcv or hiv.
boolean
C1698259 (UMLS CUI [1])
C4062778 (UMLS CUI [2])
Decompensated cirrhosis Evidence of | Liver carcinoma | Alpha one fetoprotein measurement
Item
6. patient has evidence of decompensated cirrhosis or hepatocellular carcinoma (alpha fetoprotein).
boolean
C1619727 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C2239176 (UMLS CUI [2])
C0201539 (UMLS CUI [3])
Pregnancy | Breast Feeding
Item
7. patient is pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Contraceptive methods Unwilling | Condoms, Male | Female Sterilization | Hysterectomy | Bilateral tubal ligation | Postmenopausal state | Contraception, Barrier | Intrauterine Devices | Vaginal Spermicides | Sexual Abstinence
Item
8. patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal, or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with spermicide or abstinence).
boolean
C0700589 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0009653 (UMLS CUI [2])
C0015787 (UMLS CUI [3])
C0020699 (UMLS CUI [4])
C0589114 (UMLS CUI [5])
C0232970 (UMLS CUI [6])
C0004764 (UMLS CUI [7])
C0021900 (UMLS CUI [8])
C0087145 (UMLS CUI [9])
C0036899 (UMLS CUI [10])
Substance Use Disorders
Item
9. patient has a clinically relevant history of abuse of alcohol or drugs.
boolean
C0038586 (UMLS CUI [1])
Gastrointestinal Diseases | Kidney Diseases | Decompensated liver disease | Bronchopulmonary disease | nervous system disorder | Cardiovascular Diseases | Malignant Neoplasms | Hypersensitivity
Item
10. patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
boolean
C0017178 (UMLS CUI [1])
C0022658 (UMLS CUI [2])
C4075847 (UMLS CUI [3])
C1096000 (UMLS CUI [4])
C0027765 (UMLS CUI [5])
C0007222 (UMLS CUI [6])
C0006826 (UMLS CUI [7])
C0020517 (UMLS CUI [8])
Study Subject Participation Status | Investigational New Drugs
Item
11. subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to screening visit.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pharmaceutical Preparation Traditional Chinese Medicine
Item
12. subjects who are taking any traditional chinese medication, or has been taking any traditional chinese medication within the last 2 weeks prior to screening visit.
boolean
C0013227 (UMLS CUI [1,1])
C0025124 (UMLS CUI [1,2])
Criteria Protocol Compliance Unable
Item
13. any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.
boolean
C0243161 (UMLS CUI [1,1])
C0525058 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial